Latanoprost

Latanoprost
Clinical data
Trade namesXalatan, others
AHFS/Drugs.comMonograph
MedlinePlusa697003
License data
Pregnancy
category
  • AU: B3
Routes of
administration		Topical eye drop
ATC code
Legal status
Legal status
Pharmacokinetic data
MetabolismActivation by ester hydrolysis, deactivation by beta oxidation
Onset of action3–4 hours
Elimination half-life17 minutes (plasma)
Duration of action≥ 24 hours
ExcretionMainly via kidney
Identifiers
  • Isopropyl (Z)-7-[(1R,2R,3R,5S)-3,5-dihydroxy-2- [(3R)3-hydroxy-5-phenylpentyl]-cyclopentyl] hept-5-enoate
CAS Number
PubChem CID
IUPHAR/BPS
DrugBank
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
CompTox Dashboard (EPA)
ECHA InfoCard100.162.178 Edit this at Wikidata
Chemical and physical data
FormulaC26H40O5
Molar mass432.601 g·mol−1
3D model (JSmol)
  • O=C(OC(C)C)CCC/C=C\C[C@H]2[C@@H](O)C[C@@H](O)[C@@H]2CC[C@@H](O)CCc1ccccc1
  • InChI=1S/C26H40O5/c1-19(2)31-26(30)13-9-4-3-8-12-22-23(25(29)18-24(22)28)17-16-21(27)15-14-20-10-6-5-7-11-20/h3,5-8,10-11,19,21-25,27-29H,4,9,12-18H2,1-2H3/b8-3-/t21-,22+,23+,24-,25+/m0/s1 checkY
  • Key:GGXICVAJURFBLW-CEYXHVGTSA-N checkY
  (verify)

Latanoprost, sold under the brand name Xalatan among others, is a medication used to treat increased pressure inside the eye (intraocular pressure).[5] This includes ocular hypertension and open-angle glaucoma.[5] Latanaprost is applied as eye drops to the eyes.[5] Onset of effects is usually within four hours, and they last for up to a day.[5]

Common side effects include blurry vision, redness of the eye, itchiness, and darkening of the iris.[5] Latanoprost is in the prostaglandin analogue family of medications.[5] It works by increasing the outflow of aqueous fluid from the eyes through the uveoscleral tract.[6]

Latanoprost was approved for medical use in the United States and the European Union in 1996.[5][3] It is on the World Health Organization's List of Essential Medicines.[7] Latanoprost is available as a generic medication.[8] In 2022, it was the 67th most commonly prescribed medication in the United States, with more than 9 million prescriptions.[9][10] It is available as a fixed-dose combination with netarsudil as netarsudil/latanoprost and with timolol as latanoprost/timolol.

  1. ^ "Latanoprost 50 micrograms/ml eye drops, solution - Summary of Product Characteristics (SmPC)". (emc). 1 July 2022. Archived from the original on 1 July 2022. Retrieved 1 July 2022.
  2. ^ Cite error: The named reference Xalatan FDA label was invoked but never defined (see the help page).
  3. ^ a b "Catiolanze EPAR". European Medicines Agency (EMA). 14 September 2023. Archived from the original on 5 December 2023. Retrieved 11 December 2023.
  4. ^ "Catiolanze Product information". Union Register of medicinal products. 16 November 2023. Retrieved 11 December 2023.
  5. ^ a b c d e f g "Latanoprost Monograph". The American Society of Health-System Pharmacists. Archived from the original on 28 December 2016. Retrieved 8 December 2016.
  6. ^ Patel SS, Spencer CM (1996). "Latanoprost. A review of its pharmacological properties, clinical efficacy and tolerability in the management of primary open-angle glaucoma and ocular hypertension". Drugs Aging. 9 (5): 363–378. doi:10.2165/00002512-199609050-00007. PMID 8922563. S2CID 25169085.
  7. ^ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl:10665/371090. WHO/MHP/HPS/EML/2023.02.
  8. ^ Hamilton R (2015). Tarascon Pocket Pharmacopoeia 2015 Deluxe Lab-Coat Edition. Jones & Bartlett Learning. p. 413. ISBN 9781284057560.
  9. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  10. ^ "Latanoprost Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.